Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

EPRX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 56.71M shares rose 58.9% year over year, ahead of the +27.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 9.2% from the prior quarter. Over 3 fiscal years it compounded at +27.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +58.9% holds above the trailing-twelve-month pace of +27.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
56.71M+9.2% QoQ
Last fiscal yearDec 2025
39.96M+17.8% YoY
LTMMar 2026
45.37M+27.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.9%——
1 year+17.8%——
3-year CAGR+27.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
39.96M USD
Year-over-year change
+17.8%

Weighted Avg Shares (Diluted) vs competitors

How EPRX compares with its peers on the latest reported figures

  • EPRX's LTM Mar 2026 weighted avg shares (diluted) of 45.37M shares is the 4th highest of the 10 companies compared; the peer median is 38.39M shares.
  • Its year-over-year change of +27.3% is the 4th highest of 9, against a peer median of +15.3%.
  • Over three fiscal years its annual growth of +27.5% compares with a peer median of +43.9%.
EPRX Competitors Peer median
Weighted Avg Shares (Diluted) for EPRX and competitors
Company Period LTM YoY 3-year CAGR
IVAInventiva S.A.FY2025186.8M +259.4%+65.2%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +94.5%+77.8%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026126.35M +0.5%+0.4%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 202645.37M +27.3%+27.5%
TARAProtara Therapeutics, Inc.LTM Mar 202643.36M +56.7%+56.1%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202638.39M +2.6%+14.7%
RNACCartesian Therapeutics, Inc.LTM Mar 202626.32M +15.6%+85.8%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 202621.77M +1.1%+0.7%
NTHINeonc Technologies Holdings, Inc.LTM Mar 202620.19M ——
MDWDMediWound Ltd.LTM Mar 202611.89M +14.9%+31.6%
Peer median (excluding EPRX) 38.39M+15.3%+43.9%

Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue112.38K00163.47K331.89K
Gross Profit(112.38K)00(163.47K)(331.89K)
Gross Margin—————
Research & Development7.59M13.63M15.33M16.07M29.51M
Selling, General & Admin6.97M3.99M5.63M10.92M17.1M
Operating Expenses14.65M17.62M20.97M26.99M53.33M
Depreciation & Amortization87.47K147.89K117.1K171.6K331.89K
EBITDA(17.22M)(17.86M)(20.78M)(24.95M)(53.33M)
EBITDA Margin—————
Operating Income(14.65M)(17.62M)(20.97M)(26.99M)(53.66M)
Operating Margin—————
Interest Income51.55K431.8K649.75K1.16M1.41M
Interest Expense1.02M982.86K881.05K603.17K0
Other Income / Expenses(3.68M)(1.37M)(814.93K)1.26M(212.94K)
Income Before Tax(18.33M)(18.99M)(21.78M)(25.73M)(53.87M)
Pre-Tax Margin—————
Income Tax Expense0027.42K1.8K26.65K
Net Income(18.03M)(18.49M)(21.25M)(25.49M)(53.86M)
Net Margin—————
EPS (Basic)(1.63)(0.96)(0.88)(0.76)(1.05)
EPS (Diluted)(1.63)(0.96)(0.88)(0.76)(1.05)
Weighted Avg Shares14.24M19.29M24.15M33.93M39.96M
Weighted Avg Shares (Diluted)14.24M19.29M24.15M33.93M39.96M

Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Intrinsic Alpha fair value

Locked

Current Price

$6.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.